Bergua Burgués, Juan Miguel | Hematología y Hemoterapia |

Resultados: 249
Tipo Título / Nombre Autor(es) Año
Biomarker-driven phase Ib clinical trial of OPB-111077 in acute myeloid leukemia Martínez López J, Montesinos P, López Muñoz N, Ayala R, Martínez Sánchez P..., Bergua Burgues JM 2022
Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma Tilly H, Morschhauser F, Sehn LH, Friedberg JW, Trneny M..., Bergua-Burgués JM 2022
The POLARIX Study: Polatuzumab Vedotin with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) Therapy in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma Morschhauser F, Sehn LH, Friedberg JW, Trneny S ..., Bergua Burgues JM 2021
Long-Term Subgroup Analyses from Azacitidine Vs. Decitabine in Unfit Newly Diagnosed Acute Myeloid Leukemia Patients: Results from the Pethema Registry Labrador J, Fuente A de la, Martínez-Cuadrón D, Rodríguez-Veiga R..., Bergua Burgues JM 2021
Patterns of Salvage Therapy in Patients with Acute Myeloid Leukemia Treated Upfront with Azacitidine or Decitabine: Results from the Pethema AML Registry Labrador J, Fuente A de la, Martínez-Cuadrón D, Rodríguez-Veiga R..., Bergua Burgues JM 2021
Integrated Multidimensional Flow Cytometry (MFC) and Next-Generation Sequencing (NGS) to Reconstruct Evolutionary Paterns from Dysplasia to Acute Myeloid Leukemia (AML) Simoes CP, Chillon C, Martínez -Cuadrón D, Calasanz JM..., Bergua Burgues JM 2021
First-Mind: Primary Analysis from a Phase Ib, Open-Label, Randomized Study to Assess Safety of Tafasitamab or Tafasitamab + Lenalidomide in Addition to R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma Belada D, Kopeckova K, Bergua Burgues JM, Stevens D 2021
Characteristics and Outcome of Patients with Acute Myeloid Leukemia and Trisomy 4 Kayser S, Martínez-Cuadrón D, Hanoun M, Stölzel F..., Bergua JM 2021
Nationwide Laboratory Network for AML Cross-Validated NGS Studies: Results from a Real-Life Cohort of the Pethema Group Sargas C, Ayala R, Cillon C, Larrayoz MJ..., Bergua JM 2021
Long-Term Survival after Intensive Chemotherapy or Hypomethylating Agents in AML Patients Aged 70 Years and Older: A Large Patient Data Set Study from Dataml, SAL and Pethema European Registries Recher C, Rolling C, Berard E, Bertoli S..., Bergua JM 2021